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Abstract
Background: Retroperitoneal cystadenocarcinomas are rare lesions, the majority of cases
presented as one-patient reports.
Methods: We present two cases of retroperitoneal cystadenocarcinoma, both in women of
reproductive age: one with aggressive behavior, and the remaining case, with a more indolent
clinical evolution.
Results: One case presented as pelvic tumor, was treated with surgical resection of the disease,
but manifested with recurrent disease a few months later despite use of chemotherapy. The second
case involved a patient with diagnosis of abdominal tumor; during laparotomy, a retroperitoneal
tumor was found and was totally removed. At follow-up, the patient is disease-free with no other
treatment.
Conclusion: The behavior and treatment of retroperitoneal cystadenocarcinoma are
controversial. We suggest aggressive surgery including radical hysterectomy and bilateral
salpingoopherectomy with adjuvant chemotherapy in these cases.
Background
Retroperitoneal primary cystadenocarcinomas are
extremely rare entities [1]. At present, no more than 35
cases of primary retroperitoneal mucinous cystadenocar-
cinomas have been reported in the English literature [2].
All are females, but two cases have been reported in men
[3,4].
In the majority of instances, preoperative diagnosis of
these lesions is not possible because computed tomogra-
phy (CT) scans or magnetic resonance imaging (MRI) is
not able to distinguish the exact origin of the lesion. The
most common presumptive diagnosis at surgery is
abdominal mass.
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exact prognosis continue to be uncertain. We present two
cases of primary retroperitoneal mucinous cystadenocar-
cinomas treated at a single institution; these had different
clinical presentations and totally different outcomes with
the most adequate treatment for each case according to
clinical presentation. To the best of our knowledge, these




A 36-year-old Hispanic woman had an appendicitis-asso-
ciated appendectomy at 6 years of age, and post-Cesarean
section uterine atony-related total abdominal hysterec-
tomy at age 26 years. Other medical, surgical, or family
histories were unremarkable.
The patient was seen with a 6-month history of abdomi-
nal distention and discomfort. At physical examination,
no abdominal masses or ascites were detected. A pelvic
ultrasound (US) was performed, and an adnexal cystic
mass of 19 × 16 × 12 cm with solid component was
observed in the area of the left adnexa. There was no
ascites or any other abnormalities observed in the pelvic
cavity. Serum CA-125 was 4.13 U/ml, and routine preop-
erative laboratory tests were obtained and reported as nor-
mal, as was the chest x-ray. A CT scan was conducted as
part of the preoperative evaluation; the scan confirmed
the US findings and revealed solid areas in a cystic tumor
(Figures 1a and 1b).
An exploratory laparotomy was performed with the diag-
nosis of a suspicious malignant adenexal mass. During the
procedure, a tumor measuring 19 × 16 × 12 cm was found
in the left retroperitoneal space, the tumor completely
separated from the ovaries or other intrapelvic structures.
Complete and intact removal of the lesion was obtained;
this was sent for frozen section, and was subsequently
reported as mucinous cystadenocarcinoma. At the time of
the surgery, both ovaries and fallopian tubes were grossly
normal, as were all intra-abdominal structures. The
patient's postoperative course showed no complications
or adverse events. Six courses of adjuvant chemotherapy
were administered with carboplatinum at a dose of 6 area
under the curve (AUC) and paclitaxel at 175 mgs/m2. CA-
125 was obtained after the fifth chemotherapy course and
was reported as 5.3 U/ml. A pelvic US was performed 8
months later, and a new pelvic mass measuring 7 × 6 × 6
cm at the same site was found. An exploratory laparotomy
was conducted and a sigmoid resection was required due
to a mass involving this. Infracolic omentectomy was also
carried out due to multiple nodules. The surgery was con-
sidered optimal cytoreduction with no visible lesion
remaining. The Pathology report stated mucinous cystad-
enocarcinoma.
Second-line chemotherapy was initiated with oral etopo-
side (50 mg daily for 21 days). After one cycle, disease pro-
gression was identified and the patient decided to stop
chemotherapy. Tamoxifen (20 mg/day) was instituted as
palliative management.
Pathological findings
On gross examination, an ovoid, well-defined tumor with
measurements of 19 × 16 × 12 cm with smooth grey sur-
face was received. Internal surface comprised a multilocu-
lar mass with thin walls and mucinous material only,
Computer tomography (CT) scan of pelvisFigure 1
Computer tomography (CT) scan of pelvis. a). showing normal uterus and a pelvic mass located in the area of the left adnexa. 
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ure 2). Microscopically, tumor walls were covered with a
single line of mucinous cells with small basal nuclei and
mucinous cytoplasm. In addition, ovarian-like stroma
was identified in the wall. These epithelial areas showed
transitions with intraepithelial carcinoma (Figure 3) and
areas of borderline mucinous tumor; high-grade adeno-
carcinoma with dedifferentiation in desmoplastic stroma
was identified. High-grade adenocarcinomatous compo-
nent infiltrated the tumor capsule was seen.
The recurrent tumor's surgical specimen comprised a mul-
tiorgan pelvic resection with an ill-defined white mass
with gross infiltration to muscle and fatty tissue of the pel-
vis wall, left ovary, fallopian tube, omentum, and in wall
of the colon, without lesion in the mucosa. Microscopi-
cally, high-grade adenocarcinoma similar to high-grade
areas of the previous lesion was identified, the ovary dem-
onstrating direct infiltration from the abdominal mass.
Case two
The patient, a 21-year-old female with no remarkable pre-
vious medical or surgical history complained of diffuse
abdominal discomfort 1 month prior to the patient's pres-
entation at the Emergency Service due to acute abdominal
pain and intestinal occlusion-compatible clinical data.
Abdominal and pelvic US was performed, revealing a
cystic mass with solid areas (Figure 4). An emergency
laparotomy was performed; during the surgery, a retro-
peritoneal tumor measuring 26 × 18 × 16 cm was
observed. The latter was totally removed, ascitic fluid was
detected and drained, and cytology was reported as nega-
tive for malignant cells. The tumor was located near the
pancreas, but was not attached to this organ or to any
other intra-abdominal or pelvic structures. Ovaries,
uterus, colon, and appendix were macroscopically nor-
mal, as were other intra-abdominal structures. Postopera-
tive serum CA-125 was 105 U/ml (0–21), while CA-15-3
was 32.2 U/ml (0–53) and CA-19-9 was 5.4 U/ml (0–37).
Systemic adjuvant chemotherapy was proposed; nonethe-
less, the patient refused this treatment. Therefore, close
follow-up was advised, and the patient has been seen at
the Medical Oncology Service over the last 6 months with
serial CA-125 serum levels at latest measurement of 13.3
U/ml. An abdominal CT was performed, and no evidence
of disease was found.
Pathological findings
Grossly, the tumor was a well-defined multilobular mass
of 26 × 18 cm. Cut surface exhibited a multicystic tumor
with thin walls and solid white areas. Microscopically, the
lesion was a mucinous tumor with well-differentiated
mucous glands with cribiform or papillary architecture,
and cells had pseudo-stratified, large regular nuclei with
mucinous cytoplasm, these areas demonstrating transi-
tion to cystic areas lined by a single line of mucinous cells
without atypia. No capsular invasion was identified.
Gross section of the cystic lesion shows nodular areaFigure 2
Gross section of the cystic lesion shows nodular area.Page 3 of 6
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Retroperitoneal tumors of epithelial origin are rare,
because no epithelial cells are found in this area; neverthe-
less, cases of lesions with Müllerian-type epithelium have
been reported, Roth et al., the first group in 1977[5]. The
exact origin of these tumors remains unclear [1], and
many theories have been postulated. One of the most
accepted of these is that of ectopic or supernumerary ovar-
ian tissue [1], because these tumors resemble ovarian
tumors mainly due to the presence of ovarian-like stroma.
Notwithstanding this, it is noteworthy that normal ovar-
ian tissue or remnants of normal ovarian tissue are not
found in any reported cases, including ours [1,4]. Another
issue against theory consists of the fact that at least two
cases in males have been reported previously [3,4].
Another theory is celomic metaplasia, in which some clus-
ters of celomic epithelial cells are deposited in the retro-
peritoneal area, developing an inclusion cyst. These cells
eventually experience metaplastic changes resulting in
mucinous tumors that finally have cytologic changes, thus
gaining the malignant phenotype [4,6]. Other authors
have proposed that the peritoneal epithelium possesses
the potential for Müllerian differentiation, as do all epi-
thelial ovarian tumors [7]. This concept has been sup-
ported by some authors based on immunohistochemical
and electron-microscopy evaluation of the tumors [4].
Another is the possibility of mucinous tissue overgrowing
other components of a teratoma [4].
Age-at-presentation ranges from teenaged to elderly
patients, and the most common complaint at presenta-
tion has been abdominal discomfort and a slow-growing
pelvic or abdominal mass [4,6]. In one of our cases, pres-
entation was acute abdominal pain and intestinal occlu-
sion. Matsubara in his review mentions that no cases
examined involved severe pain; [6] therefore, we might
say that this is the first case reported to date with this clin-
ical presentation.
Preoperative diagnosis is rarely suspected because of the
non-specific symptoms and the scarce aid of imaging
examinations. Although US, CT scan, and MRI clearly
detect cystic masses in ovarian or pelvic organs, diagnosis
of retroperitoneal tumor is extremely difficult. This was
mentioned by Matsubara et al., in that the authors were
solely able to find two reports in the literature with suspi-
cious preoperative retroperitoneal tumor in their review
of 16 cases from 1966 to the report in 2005 [6]. Others
authors such as Thamboo mentioned that diagnosis of
retroperitoneal cyst was suspected by means of CT scan
[3]. Although no specific data have been reported regard-
ing the characteristics of lesions that may suggest a retro-
peritoneal tumor, displacement of ureter, kidney, great
vessels, or colon may be of some aid in the preoperative
diagnosis [6].
Tumor markers are not very helpful in differentiating the
exact origin of the lesion, because CA-125, CA19-9 may or
may not be elevated and may or may not have increased
values in other neoplasms such as epithelial ovarian
tumor (serous or mucinous). On the other hand, tumor
markers help in detecting a recurrent tumor, as in ovarian
cancer or colon cancer [4].
It is clear that surgical treatment of these tumors is the cor-
nerstone, but the question remains: how extensive must
the surgery be? Everyone agrees on total removal of the
lesion, but some authors such as Gotoh et al., [7] recom-
mend oophorectomy to improve survival. Lee et al., [8]
recommend not only oophorectomy, but also total hyster-
ectomy. On the other end of the surgical-treatment spec-
trum, Kessler et al., [9] recommend that if uterus and
ovaries are macroscopically normal and because follow-
up in the majority of reported cases is deficient and the
serious consequences of this surgical procedure, hysterec-
tomy and salpingo-oophorectomy cannot be justified for
treatment of primary retroperitoneal mucinous cystaden-
ocarcinomas [9]. The only reason for this procedure to be
performed is in postmenopausal women or patients who
have completed child-bearing. We can also find reports
presenting more conservative surgery, such as that pro-
posed by Law et al., who advocate for laparoscopic exci-
sion of the tumor and complete evaluation of abdominal
and pelvic organs, sparing fertility in these women [10].
Adjuvant chemotherapy is not a standard treatment and is
beneficial solely in cases in which the tumor has been rup-
tured during surgery [9], or when invasion to adjacent
Microscopically, the tumor shows transition between benign and malignant areas of the mucinous tumor (H matoxilin andeosin tai  20×)Figure 3
Microscopically, the tumor shows transition between benign 
and malignant areas of the mucinous tumor (Hematoxilin and 
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treatment is evidence that primary retroperitoneal muci-
nous cystadenocarcinomas and ovarian mucinous tumor
have similar mechanisms in their histogenesis; this was
reported by Tenti et al. [11], who had found K-ras onco-
gene mutation at codon 12 and demonstrated immunore-
activity for intestinal cell markers. In one of our cases, in
which the tumor was completely excised without rupture
but with capsular invasion, chemotherapy was given with
no benefit because the patient experienced recurrence a
few months after completion of adjuvancy. We also had
the remaining case with no complementary treatment; the
patient is at present disease-free. Thus, the questions
remain: In which patients may recurrence occur? Which
cases must have addition of cytotoxic chemotherapy? Or
shall we just have close follow-up of these patients, as pro-
posed by some authors [4,12]?
The answers of these questions must wait for the moment
until we can determine whether the patient is at risk for
recurrence or not, and further study is needed to establish
optimal-treatment protocols on these rare neoplasms. We
are in favor of aggressive adjuvant chemotherapy with
hysterectomy and bilateral oophorectomy only when
macroscopic involvement of these structures is found dur-
ing the procedure.
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Ultrasound (US) reveals a cystic mass with solid areas in the second caseFigure 4
Ultrasound (US) reveals a cystic mass with solid areas in the second case.Page 5 of 6
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